AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36474017 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (2 g)
Number of subjects: 8
Study 36474210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated sex work stigma
Number of subjects: 1373
Study 36474210 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe internalized sex work stigma
Number of subjects: 1373
Study 36474210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted HIV stigma
Number of subjects: 1373
Study 36474210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted sex work stigma
Number of subjects: 1373
Study 36474210 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated HIV stigma
Number of subjects: 1373
Study 36474257 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk assessment (HRA) with integrated guideline-based clinical decision support (CDS)
Number of subjects: 1829
Study 36474269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary exposure risk questionnaire
Number of subjects: 404
Study 36474266 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily AChE levels
Number of subjects: 272
Study 36474266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower enrollment BChE levels
Number of subjects: 272
Study 36474266 — intervention group
Group type: EXPERIMENTAL
Intervention: AChE, AChE/Hgb, and BChE levels
Number of subjects: 272
Study 36474435 — intervention group
Group type: EXPERIMENTAL
Intervention: c.1342C>G, g.41635A>G and c.2699C>T polymorphisms
Number of subjects: 1000
Study 36474435 — intervention group
Group type: EXPERIMENTAL
Intervention: 41635A-allele
Number of subjects: 1000
Study 36474435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1342G-allele
Number of subjects: 1000
Study 36474435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1342CG genotype
Number of subjects: 1000
Study 36474510 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs (group S)
Number of subjects: 105
Study 36474510 — intervention group
Group type: COMPARATOR
Intervention: Ambient operating room noise (group N)
Number of subjects: 105
Study 36474510 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (group M)
Number of subjects: 105
Study 36474510 — intervention group
Group type: COMPARATOR
Intervention: Silence and operating noise (control)
Number of subjects: 105
Study 36474875 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) cycling for 6 weeks
Number of subjects: 16
Study 36474880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining program aimed to decrease peak axial acceleration of the lower leg by 20%
Number of subjects: 40
Study 36474880 — intervention group
Group type: COMPARATOR
Intervention: Traditional walking program
Number of subjects: 40
Study 36474952 — intervention group
Group type: COMPARATOR
Intervention: Tanezumab
Number of subjects: 0
Study 36474952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36474952 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study 36474966 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (150 minutes or more per week)
Number of subjects: 0
Study 36474966 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (30 to 150 minutes per week)
Number of subjects: 0
Study 36474966 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically inactive (less than 30 minutes per week)
Number of subjects: 0
Study 36475016 — intervention group
Group type: EXPERIMENTAL
Intervention: NL intervention (NL-I)
Number of subjects: 0
Study 36475018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measurement in WRA from upper-middle and high-income countries
Number of subjects: 43
Study 36475018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measurement in WRA from low- and lower-middle income countries
Number of subjects: 43
Study 36475018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measurement in PSC
Number of subjects: 43
Study 36475019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-upper arm circumference (MUAC) measurement
Number of subjects: 1167
Study 36475019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-upper arm circumference (MUAC)
Number of subjects: 1167
Study 36475019 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference (HC)
Number of subjects: 1167
Study 36475114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.2 mg/kg intravenously daily (n = 70)
Number of subjects: 142
Study 36475114 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 6 mg daily (n = 72)
Number of subjects: 142
Study 36475473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut BP-SES
Number of subjects: 2341
Study 36475473 — intervention group
Group type: COMPARATOR
Intervention: Thick-strut BP-BES
Number of subjects: 2341
Study 36475777 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (N-terminal pro-B-type natriuretic peptide)
Number of subjects: 7038
Study 36475777 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 protein biomarkers associated with new-onset HFpEF
Number of subjects: 7038
Study 36475777 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 biomarkers associated with new-onset HFrEF
Number of subjects: 7038
Study 36476135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily for 17 weeks
Number of subjects: 35
Study 36476135 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 35
Study 36476289 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary drainage procedure (Group 2)
Number of subjects: 11037
Study 36476289 — intervention group
Group type: COMPARATOR
Intervention: Pleural effusion only (Group 1)
Number of subjects: 11037
Study 36476289 — intervention group
Group type: COMPARATOR
Intervention: No pleural effusion (Group 0)
Number of subjects: 11037
Study 36476454 — intervention group
Group type: COMPARATOR
Intervention: HIV/HBV
Number of subjects: 5733
Study 36476454 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HBV/HCV
Number of subjects: 5733
Study 36476454 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014 or later follow-up
Number of subjects: 5733
Study 36476454 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 5733
Study 36476452 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PWH
Number of subjects: 294
Study 36476452 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccination in controls (HIV-negative individuals)
Number of subjects: 294
Study 36476492 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (SM) programme
Number of subjects: 270
Study 36476492 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial factors
Number of subjects: 270
Study 36476498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 0
Study 36476605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group using continuous glucose monitor (CGM), insulin pen, activity tracker, and smartphone applications.
Number of subjects: 0
Study 36476605 — intervention group
Group type: COMPARATOR
Intervention: Usual care group using blinded CGM for the first and last 20 days and a blinded insulin pen for the entire period.
Number of subjects: 0
Study 36476605 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Number of subjects: 0
Study 36476605 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study 36476609 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network-based group intervention
Number of subjects: 40
Study 36476609 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 36476970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask
Number of subjects: 35
Study 36476970 — intervention group
Group type: COMPARATOR
Intervention: No-Mask
Number of subjects: 35
Study 36477014 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week digital intervention program for T2DM self-management
Number of subjects: 180
Study 36477031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs)
Number of subjects: 168
Study 36477031 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg)
Number of subjects: 168
Study 36477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Catquest-9SF questionnaire
Number of subjects: 100
Study 36477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Catquest-9SF questionnaire
Number of subjects: 100
Study 36477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Catquest-9SF logit score
Number of subjects: 100
Study 36477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative spherical equivalent
Number of subjects: 100
Study 36477416 — intervention group
Group type: EXPERIMENTAL
Intervention: 5R-STS performance
Number of subjects: 240
Study 36477458 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ibuprofen treatment
Number of subjects: 273
Study 36477458 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 273
Study 36477555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (300 mg) in combination with durvalumab (STRIDE regimen)
Number of subjects: 0
Study 36477643 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic CRS/HIPEC
Number of subjects: 18
Study 36477706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 30
Study 36477706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 30
Study 36477706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 30
Study 36477706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 30
Study 36477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cutaneous involvement during CAPS
Number of subjects: 65
Study 36477870 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib 300 mg once daily orally
Number of subjects: 59
Study 36477975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamibarotene plus azacitidine
Number of subjects: 51
Study 36477975 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine monotherapy
Number of subjects: 51
Study 36478144 — intervention group
Group type: EXPERIMENTAL
Intervention: VGRSD
Number of subjects: 10
Study 36478179 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ΔP4 (drop in serum progesterone from OPU +3 days to OPU +5 days)
Number of subjects: 340
Study 36478179 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ΔP4 (increase in serum progesterone from OPU +3 days to OPU +5 days)
Number of subjects: 340
Study 36478179 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ΔP4
Number of subjects: 340
Study 36478179 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of ΔP4 in negative ΔP4 patients
Number of subjects: 340
Study 36478334 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab 800 mg/m² intravenous
Number of subjects: 18
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 873
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 873
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 873
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 873
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and Metronidazole
Number of subjects: 873
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and Fluoroquinolone
Number of subjects: 873
Study 36478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, Metronidazole, and Fluoroquinolone
Number of subjects: 873
Study 36479110 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus camrelizumab
Number of subjects: 37
Study 36479110 — intervention group
Group type: COMPARATOR
Intervention: CCRT treatment
Number of subjects: 37
Study 36479231 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-613 (devimistat) combined with radiation therapy (RT)
Number of subjects: 2
Study 36479231 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-613 combined with gemcitabine or 5-fluorouracil in the presence of 2 Gy RT
Number of subjects: 2
Study 36479231 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 2
Study 36479231 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI-613 (devimistat) combined with RT
Number of subjects: 2
Study 36479375 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interviews addressing maternal health and well-being, parental stress, COVID-related barriers, and access to essential services.
Number of subjects: 40
Study 36479375 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding psychosocial stressors and developing interventions.
Number of subjects: 40
Study 36479375 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering continual social services as a potential solution.
Number of subjects: 40
Study 36479544 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 cycles of rituximab combined with 6 cycles of bendamustine (BR)
Number of subjects: 68
Study 36479544 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab
Number of subjects: 68
Study 36479563 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrioventricular coupling index (LACI) measured as the ratio of the LA end-diastolic volume to the LV end-diastolic volume.
Number of subjects: 2087
Study 36479658 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month, peer-delivered, remote intervention to increase physical activity (PA)
Number of subjects: 34
Study 36479951 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36480111 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl (2.5 to 10 mg)
Number of subjects: 41
Study 36480274 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) alone
Number of subjects: 330
Study 36480274 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) combined with Group Problem Management Plus (GPM+)
Number of subjects: 330
Study 36480274 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 330
Study 36480388 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CPTs with 10 puffs price-frame
Number of subjects: 0
Study 36480388 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CPTs with 1 mL price-frame
Number of subjects: 0
Study 36480395 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economic measure drug demand
Number of subjects: 0
Study 36480395 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural measure late positive potential (LPP)
Number of subjects: 0
Study 36480395 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of drug demand and LPP
Number of subjects: 0
Study 36480413 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain induction
Number of subjects: 0
Study 36480413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pain induction)
Number of subjects: 0
Study 36480452 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (0.5 to 5 IU administered as an intravenous bolus over 1 minute)
Number of subjects: 30
Study 36480463 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous secretory leukocyte protease inhibitor (SLPI)
Number of subjects: 0
Study 36480463 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular SLPI uptake by monocytes
Number of subjects: 0
Study 36481125 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 15 mg once daily
Number of subjects: 11
Study 36481475 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abstinence
Number of subjects: 320
Study 36481736 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily
Number of subjects: 33
Study 36481736 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus famitinib
Number of subjects: 33
Study 36481832 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping with the Advisor™ HD Grid mapping catheter and radiofrequency (RF) ablation
Number of subjects: 334
Study 36481832 — intervention group
Group type: EXPERIMENTAL
Intervention: PV-only ablation strategy
Number of subjects: 334
Study 36481832 — intervention group
Group type: EXPERIMENTAL
Intervention: PV ablation and additional lesions
Number of subjects: 334
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI < 25 kg/m²
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: Annualized percent change in body weight
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: Annualized change in percent predicted forced vital capacity (%FVC)
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent predicted diffusing capacity for carbon monoxide
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk distance
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause hospitalizations
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory-related hospitalizations
Number of subjects: 600
Study 36481866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exacerbations
Number of subjects: 600
Study 36482076 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD201
Number of subjects: 6
Study 36482076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine® (40 mg/ml)
Number of subjects: 6
Study 36482188 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation with a schedule of 3 Gray per fraction (minimum 18 Gy/6 fractions, maximum 30 Gy/10 fractions) with a maximum cumulative spinal dose of 100 Gy
Number of subjects: 22
Study 36482188 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Number of subjects: 22
Study 36482193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rucaparib 600 mg twice daily
Number of subjects: 54
Study 36482216 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + additional rifampicin (up to 35 mg/kg/d) + linezolid 1200 mg/d reducing after 28 days to 600 mg/d
Number of subjects: 52
Study 36482216 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + additional rifampicin (up to 35 mg/kg/d) + linezolid 1200 mg/d reducing after 28 days to 600 mg/d + aspirin 1000 mg/d
Number of subjects: 52
Study 36482216 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 52
Study 36482345 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus paclitaxel and cisplatin (TP)
Number of subjects: 47
Study 36482352 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly injectable formulation (AOM) for 12 months
Number of subjects: 0
Study 36482369 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with pulse amplitudes of 600, 700, and 800 mA
Number of subjects: 54
Study 36482482 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart scans performed in the first ten days after birth (DABs)
Number of subjects: 40
Study 36482482 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of participating preterm infants' parents in neonatal unit diaries
Number of subjects: 40
Study 36482482 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with parents and health professionals
Number of subjects: 40
Study 36482505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination of previously infected persons
Number of subjects: 0
Study 36482505 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 anti-spike antibody levels in the nose
Number of subjects: 0
Study 36482505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and saliva anti-spike antibody levels
Number of subjects: 0
Study 36482505 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma anti-spike antibody
Number of subjects: 0
Study 36482505 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine given peripherally
Number of subjects: 0
Study 36482505 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently elevated SARS-CoV-2 antibody in plasma
Number of subjects: 0
Study 36482560 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (25 mg/d for 52 weeks)
Number of subjects: 0
Study 36482560 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 36482815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 mg twice daily) with methylprednisolone (40 mg every other day)
Number of subjects: 29
Study 36482815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib with methylprednisolone
Number of subjects: 29
Study 36482870 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise testing (GXT)
Number of subjects: 45
Study 36483037 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccine containing peptides derived from PD-L1 and PD-L2
Number of subjects: 19
Study 36483037 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccine
Number of subjects: 19
Study 36483043 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study 36483043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36483127 — intervention group
Group type: EXPERIMENTAL
Intervention: ON (on-campus) group
Number of subjects: 117
Study 36483127 — intervention group
Group type: COMPARATOR
Intervention: OFF (off-campus) group
Number of subjects: 117
Study 36483246 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from co-workers
Number of subjects: 1852
Study 36483246 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 1852
Study 36483246 — intervention group
Group type: EXPERIMENTAL
Intervention: Job stressors
Number of subjects: 1852
Study 36483268 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment delivered to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 596